Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Clinical Pre-screening Protocol for Ovarian Cancer

Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with histological confirmed epithelia ovarian cancer - Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. - Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting - FFPE tumor tissue available Who Should NOT Join This Trial: - Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy. - Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with histological confirmed epithelia ovarian cancer * Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. * Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting * FFPE tumor tissue available Exclusion Criteria: * Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy. * Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator

Treatments Being Tested

DEVICE

Drug Response Predictor® (DRP)

A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.

Locations (5)

Dana-Farber Cancer Institute
Boston, Massachusetts, United States
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Swedish Center for Research and Innovation
Seattle, Washington, United States
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
London, United Kingdom